Brief: Nuvectis Pharma With ENGOT, GOG Foundation To Conduct NXP800 Phase 1b Clinical Trial
04/01/2023 13:09
Jan 4 (Reuters) - Nuvectis Pharma Inc NVCT.O :
* NUVECTIS PHARMA ANNOUNCES COLLABORATION WITH ENGOT AND GOG
FOUNDATION TO CONDUCT THE NXP800 PHASE 1B CLINICAL TRIAL IN
ARID1A-MUTATED OVARIAN CARCINOMA IN EUROPE AND IN THE UNITED
STATES
Source text for Eikon: ID:nGNX6PDVjV
Further company coverage: NVCT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nuvectis Pharma
See all newsNuvectis Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Nuvectis Pharma Inc expected to post a loss of 26 cents a share - Earnings Preview
Brief: Ciprocopan (NXP100) Receives Marketing Approval In China For The Treatment Of Patients With PNH Previously Untreated With Complement Inhibitors
U.S. STOCKS ON THE MOVE-Chip stocks, Unicycive, Roblox
U.S. STOCKS ON THE MOVE-AMD, Roblox, Olin